Tirzepatide 5mg

Tirzepatide Structure

Source:pubchem

For Research Use Only – Not for Human or Veterinary Use

Product Summary

Tirzepatide is a dual incretin mimetic that simultaneously activates the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. By harnessing complementary gut-hormone pathways, the peptide has demonstrated potent insulinotropic, anorectic, and weight-reducing effects in contemporary pre-clinical models. The present 5 mg presentation is supplied as a high-purity, lyophilized powder strictly for in-vitro and exploratory in-vivo research on metabolic regulation, obesity, and cardiometabolic risk.

Key Details

Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈ 

Molecular Weight: 4813.5 g/mol 

CAS Number: 2023788-19-2

Potential Research Applications

1. Metabolic & Endocrine Regulation
   • Characterization of dual GLP-1/GIP receptor agonism on insulin secretion, glucagon suppression, and energy expenditure.
2. Obesity & NAFLD Models
   • Evaluation of chronic tirzepatide exposure on body-weight dynamics, hepatic lipid accumulation, and inflammatory biomarkers in high-fat–diet rodents.
3. Cardiovascular & Renal Profiling
   • Investigation into endothelial function, blood-pressure modulation, and albuminuria attenuation associated with incretin co-agonism.
4. Signal-Transduction Mapping
   • Dissection of downstream cAMP/PKA, PI3K/Akt, and MAPK pathways activated by concurrent GLP-1R and GIPR signaling in islet and adipose tissue cultures.

Safety and Compliance

1. Research Use Only

• Tirzepatide 5mgis not approved for human consumption or therapeutic use. It is intended exclusively for laboratory-based and scientific investigations.

2. Regulatory Status

• Always follow national, regional, or institutional regulations when purchasing, storing, and using this compound.

3. Liability

• Users assume full responsibility for determining the suitability of Tirzepatide 5mgin their applications. The manufacturer and distributor disclaim all liability for improper or unauthorized usage.

References

1. Gonzalez-Ramirez, P. & Huang, Y. (2024). “Dual-incretin agonists: metabolic outcomes and mechanistic insights.” Trends Endocrinol. Metab. 35 (4), 233-245.
2. McIntyre, A. et al. (2023). “Comparative efficacy of tirzepatide versus semaglutide in murine models of diet-induced obesity.” Metabolism Research 19 (2), 87-96.

Disclaimer

All product information is provided for research and informational purposes only. 

Tirzepatide 5mg is not designated for medical, diagnostic, or therapeutic applications. Users must operate in accordance with the appropriate safety regulations and protocols. The seller disclaims any responsibility for misuse or mishandling of the product.